Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance. We hypothesized that treatment with caboz...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Oncol
Main Authors: Reckamp, Karen L., Frankel, Paul H., Ruel, Nora, Mack, Philip C., Gitlitz, Barbara J., Li, Tianhong, Koczywas, Marianna, Gadgeel, Shirish M., Cristea, Mihaela C., Belani, Chandra P., Newman, Edward M., Gandara, David R., Lara, Primo N.
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421302/
https://ncbi.nlm.nih.gov/pubmed/30915273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00132
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki